Gilead's FXR agonist among NASH therapies highlighted ahead of AASLD

Abstracts with Phase II data for several non-alcoholic steatohepatitis therapies were published ahead of next month's American Association for the Study of Liver Diseases meeting in San Francisco.

Among them, Gilead Sciences Inc. (NASDAQ:GILD) reported new data for GS-9674, its non-steroidal agonist of farnesoid X receptor (FXR; NR1H4).